Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to evaluate the efficacy of TISSEEL Lyo for haemostasis in patients receiving peripheral vascular prosthetic expanded polytetrafluoroethylene (ePTFE) conduits, as compared to a control arm treated with manual compression with surgical gauze pads.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TISSEEL Lyo | Experimental | Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System. |
|
| Manual compression with surgical gauze pads | Active Comparator | Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TISSEEL Lyo | Biological | The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants achieving hemostasis at 4 minutes after treatment | Performed on suture line. | Day 0 (4 minutes post-treatment to closure of surgical wound) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants achieving hemostasis at 6 minutes after treatment | Performed on suture line. | Day 0 (6 minutes post-treatment to closure of surgical wound) |
| Number of participants achieving hemostasis at 10 minutes after treatment |
Not provided
Inclusion Criteria:
Signed informed consent;
Male or female ≥ 18 ages;
Patients undergoing primary vascular surgery (i.e., conduit placement with an ePTFE graft), including the following:
Arterio-arterial-bypass;
Arteriovenous shunting for dialysis access in the upper or lower extremity;
Intraoperative inclusion criterion:
Exclusion Criteria:
Intraoperative exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Baxter Investigational Site | Moscow | Russia | ||||
| Baxter Investigational Site |
Not provided
| ID | Term |
|---|---|
| D012997 | Solvents |
| D013917 | Thrombin |
| ID | Term |
|---|---|
| D020313 | Specialty Uses of Chemicals |
| D020164 | Chemical Actions and Uses |
| D012697 | Serine Endopeptidases |
| D010450 | Endopeptidases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Manual compression with surgical gauze pads | Procedure | Surgical 4x4 inches gauze pads |
|
Performed on suture line.
| Day 0 (10 minutes post-treatment to closure of surgical wound) |
| Number of participants with intraoperative re-bleeding after hemostasis | Performed on suture line. | Day 0 (intraoperative) |
| Number of participants with postoperative re-bleeding after hemostasis | Performed on suture line. Requires surgical re-exploration. | Day 1 (postoperative) |
| Novosibirsk |
| Russia |
| Baxter Investigational Site | Rostov-on-Don | Russia |
| Baxter Investigational Site | Ryazan | Russia |
| Baxter Investigational Site | Saint Petersburg | Russia |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D057057 | Serine Proteases |
| D001779 | Blood Coagulation Factors |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001685 | Biological Factors |